Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Olmesartan Prices Treble In UK

Pricewatch UK – February 2021

Executive Summary

Average UK trade prices of olmesartan as much as trebled across multiple presentations in the second month of 2021. However, this was not the only triple-digit price rise seen during February, WaveData reveals.

You may also be interested in...



Multiple Molecules See UK Prices Double In March

Etoricoxib, letrozole and trimethoprim experienced triple-digit rises in their average UK trade prices in March, according to the latest figures from WaveData.

Zonisamide Zooms Up In October

Zonisamide presentations saw average price increases of as much as five times in October, according to the latest UK figures from WaveData.

US Bill Seeks To Eliminate Biosimilar Interchangeability Trial Burden

Sen. Mike Lee, R-UT, has introduced draft legislation in the US that would stop the FDA from requiring biosimilars to conduct ‘unnecessary’ switching studies in order to obtain an interchangeability designation.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel